🇺🇸 FDA
Patent

US 12215320

Compositions and methods for gene editing by targeting transferrin

granted A61KA61K35/407A61K48/0008

Quick answer

US patent 12215320 (Compositions and methods for gene editing by targeting transferrin) held by CRISPR THERAPEUTICS AG expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRISPR THERAPEUTICS AG
Grant date
Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K35/407, A61K48/0008, A61K48/005